Leeds Institute for Molecular Medicine, University of Leeds, Leeds, UK.
Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205. Epub 2011 Dec 15.
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host antitumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response.
溶瘤病毒（OV）是癌症治疗的一种有前途的方法，目前有几种正在进行随机临床试验。麻疹病毒（MV）尚未在人类黑色素瘤模型中进行测试。本研究证明了 MV 对人类黑色素瘤的疗效。人们越来越认识到，OV 治疗的一个重要组成部分是募集宿主抗肿瘤免疫反应，包括先天和适应性免疫反应。MV 介导的黑色素瘤细胞死亡是一个炎症过程，导致包括 1 型干扰素和强效危险信号 HMGB1 在内的炎症细胞因子的释放。在这里，我们使用人体体外模型证明 MV 增强了先天抗肿瘤活性，并且 MV 介导的黑色素瘤细胞死亡能够刺激黑色素瘤特异性适应性免疫反应。
